- Home
- LEO vs GOSS Comparison
LEO vs GOSS Comparison
Compare LEO & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEO
- GOSS
- Stock Information
- Founded
- LEO 1987
- GOSS 2015
- Country
- LEO United States
- GOSS United States
- Employees
- LEO N/A
- GOSS N/A
- Industry
- LEO Trusts Except Educational Religious and Charitable
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- LEO Finance
- GOSS Health Care
- Exchange
- LEO Nasdaq
- GOSS Nasdaq
- Market Cap
- LEO 362.5M
- GOSS 347.8M
- IPO Year
- LEO N/A
- GOSS 2019
- Fundamental
- Price
- LEO $5.89
- GOSS $2.34
- Analyst Decision
- LEO
- GOSS Strong Buy
- Analyst Count
- LEO 0
- GOSS 4
- Target Price
- LEO N/A
- GOSS $8.50
- AVG Volume (30 Days)
- LEO 200.2K
- GOSS 3.0M
- Earning Date
- LEO 01-01-0001
- GOSS 08-05-2025
- Dividend Yield
- LEO 4.01%
- GOSS N/A
- EPS Growth
- LEO N/A
- GOSS N/A
- EPS
- LEO 0.04
- GOSS N/A
- Revenue
- LEO N/A
- GOSS $40,237,000.00
- Revenue This Year
- LEO N/A
- GOSS N/A
- Revenue Next Year
- LEO N/A
- GOSS $63.97
- P/E Ratio
- LEO $152.00
- GOSS N/A
- Revenue Growth
- LEO N/A
- GOSS N/A
- 52 Week Low
- LEO $4.98
- GOSS $0.66
- 52 Week High
- LEO $6.50
- GOSS $2.34
- Technical
- Relative Strength Index (RSI)
- LEO 53.93
- GOSS 70.49
- Support Level
- LEO $5.82
- GOSS $1.88
- Resistance Level
- LEO $5.89
- GOSS $2.03
- Average True Range (ATR)
- LEO 0.05
- GOSS 0.16
- MACD
- LEO -0.01
- GOSS 0.01
- Stochastic Oscillator
- LEO 53.85
- GOSS 98.54
About LEO BNY Mellon Strategic Municipals Inc.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products are Equity and Fixed Income Mutual Funds, Retail Money Market Funds, Government/Treasury Money Market Funds, Institutional Money Market Funds, and others. BNY Mellon and its affiliates, including BNYM Investment Adviser, INA and others involved in the management, sales, investment activities, business operations or distribution of the Fund, are engaged in businesses and have interests other than that of managing the Fund.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.